David Fajgenbaum, MD, MBA, MSc | Keynote

Released September 10

Recent Features:
The Inquirer
Good Morning America
New York Post

About David Fajgenbaum, MD, MBA, MSc

David Fajgenbaum, MD, MBA, MSc, is the co-founder and Executive Director of the Castleman Disease Collaborative Network (CDCN) and Assistant Professor of Medicine in Translational Medicine & Human Genetics at the University of Pennsylvania, where he is one of the youngest individuals to be appointed to the faculty at Penn Medicine. An NIH-funded researcher, he has dedicated his life to discovering new treatments for deadly hyperinflammatory disorders like idiopathic multicentric Castleman disease (iMCD), which he was diagnosed with during medical school. After spending months hospitalized in critical condition, having his last rites read, and having four deadly relapses, he is now in his longest remission ever thanks to a drug that he identified as a candidate treatment in the lab. He has recently launched a clinical trial to study this drug, sirolimus, in other treatment-refractory iMCD patients. Among the top 1 percent youngest grant awardees of an R01, Dr. Fajgenbaum has published research in the Journal of Clinical Investigation, Blood, and the Lancet Haematology, among others and been profiled by The New York Times, Forbes 30 Under 30 list, Science, Good Morning America, and the Today Show. Dr. Fajgenbaum earned a BS from Georgetown University magna cum laude with honors and distinction, MSc from the University of Oxford, MD from the University of Pennsylvania Medical School, and MBA from The Wharton School.

Every Life Sciences Future – BioPharm attendee will receive a complimentary copy of Dr. Fajgenbaum’s memoir and he will be available for a book signing.